title: [3H]CGP 61594, the first photoaffinity ligand for the glycine site of NMDA receptors.
abstract: Activation of NMDA receptors requires the presence of glycine as a coagonist which binds to a site that is allosterically linked to the glutamate binding site. To identify the protein constituents of the glycine binding site in situ the photoaffinity label [3H]CGP 61594 was synthesized. In reversible binding assays using crude rat brain membranes, [3H]CGP 61594 labeled with high affinity (K(D) = 23 nM) the glycine site of the NMDA receptor. This was evident from the Scatchard analysis, the displacing potencies of various glycine site ligands and the allosteric modulation of [3H]CGP 61594 binding by ligands of the glutamate and polyamine sites. Electrophysiological experiments in a neocortical slice preparation identified CGP 61594 as a glycine antagonist. Upon UV-irradiation, a protein band of 115 kDa was specifically photolabeled by [3H]CGP 61594 in brain membrane preparations. The photolabeled protein was identified as the NR1 subunit of the NMDA receptor by NR1 subunit-specific immunoaffinity chromatography. Thus, [3H]CGP 61594 is the first photoaffinity label for the glycine site of NMDA receptors. It will serve as a tool for the identification of structural elements that are involved in the formation of the glycine binding domain of NMDA receptors in situ and will thereby complement the mutational analysis of recombinant receptors.
authors.affiliation: Institute of Pharmacology, ETH and University of Zurich, Switzerland.
authors.forename: D
authors.initials: D
authors.lastname: Benke
authors.forename: M
authors.initials: M
authors.lastname: Honer
authors.forename: R
authors.initials: R
authors.lastname: Heckendorn
authors.forename: M F
authors.initials: MF
authors.lastname: Pozza
authors.forename: H
authors.initials: H
authors.lastname: Allgeier
authors.forename: C
authors.initials: C
authors.lastname: Angst
authors.forename: H
authors.initials: H
authors.lastname: Mohler
mesh_terms: D000345:Affinity Labels; D000818:Animals; D001386:Azides / Q000138:chemical synthesis / Q000493:pharmacokinetics* / Q000494:pharmacology*; D001665:Binding Sites; D001667:Binding, Competitive; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D002462:Cell Membrane / Q000378:metabolism; D002540:Cerebral Cortex / Q000502:physiology; D004594:Electrophysiology; D005071:Evoked Potentials / Q000187:drug effects; D018690:Excitatory Amino Acid Agonists / Q000493:pharmacokinetics* / Q000494:pharmacology; D005998:Glycine / Q000378:metabolism*; D006624:Hippocampus / Q000502:physiology; D066298:In Vitro Techniques; D007700:Kinetics; D008024:Ligands; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology; D019579:Neocortex / Q000502:physiology; D011804:Quinolines / Q000138:chemical synthesis / Q000493:pharmacokinetics* / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*; D012694:Serine / Q000494:pharmacology; D014316:Tritium
chemical_list: D000345:Affinity Labels; D001386:Azides; C112115:CGP 61594; D018690:Excitatory Amino Acid Agonists; D008024:Ligands; D011804:Quinolines; D016194:Receptors, N-Methyl-D-Aspartate; D014316:Tritium; D012694:Serine; D016202:N-Methylaspartate; D005998:Glycine